<DOC>
	<DOCNO>NCT00717340</DOCNO>
	<brief_summary>This standard Phase 1b 2a , multi-center , study design examine safety , tolerability , maximum tolerate dose , overall response rate tivozanib ( AV-951 ) paclitaxel breast cancer .</brief_summary>
	<brief_title>A Phase 1b/2a , Open-Label , Multi-Center Study Tivozanib ( AV-951 ) Combination With Paclitaxel Subjects With Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>This standard Phase 1b 2a , multi-center , study design examine safety , tolerability , maximum tolerate dose , overall response rate tivozanib ( AV-951 ) paclitaxel breast cancer . In Phase 1b study , dose tivozanib ( AV-951 ) escalate 0.5 mg/day 1.5 mg /day . All subject receive dos weekly paclitaxel chemotherapy . The Phase 2a study portion study conduct .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . ≥ 18yearold female 2 . Histologically cytologically document invasive breast cancer 3 . Documented progressive disease ( Phase 1b study ) OR document metastatic disease ( Phase 2a study ) 4 . Prior Treatment : Phase 1b study : No 4 prior chemotherapy treatment , 1 prior taxanebased regimen metastatic disease . There limit number prior hormonal biological treatment . Phaes 2a study : No prior chemotherapy biological therapy metastatic breast cancer . There limit number prior hormonal treatment . Prior adjuvant chemotherapy biological therapy count number prior treatment , unless recurrence occurs within 12 month last dose adjuvant therapy , case count 1 prior therapy ; adjuvant treatment taxane allow . 5 . Measurable evaluable disease RECIST criterion ( Phase 1b study ) ( see Appendix A ) . Subjects enrol Phase 2a study require measureable disease accord RECIST . 6 . No prior VEGFTKI drug sunitinib , sorafenib , AZ2171 , AG013736 , GW786034 , ZD6474 AMG706 , PTK/ZK similar agent . 7 . No treatment bevacizumab within 4 week prior start protocol therapy , prior treatment VEGF binding antibody VEGFtrap . 8 . No treatment follow agent within 3 week prior start protocol therapy : Chemotherapy ( least 6 week nitrosoureas , mitomycin C , liposomal doxorubicin ) Other signal transduction inhibitor monoclonal antibody Immunotherapy biological response modifier Any experimental therapy 9 . No treatment radiotherapy within 2 week ( involve &lt; 25 % bone marrow ) , 4 week ( involve ≥ 25 % bone marrow ) prior start protocol therapy . 10 . Resolution toxicities 11 . ECOG performance status ≤ 2 life expectancy ≥ 3 month . 12 . Signed date write informed consent 1 . Known hypersensitivity paclitaxel component paclitaxel formulation 2 . Pregnant lactating woman ; fertile subject must use effective contraception ( barrier method ) study 3 month thereafter . All subject must agree use highly effective method contraception ( include partner ) . Effective birth control include ( ) IUD plus 1 barrier method , ( b ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm . ) Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , consider effective study . 3 . Subjects symptomatic CNS metastasis . Subjects treat brain metastasis remain stable least 3 month without steroid allow . Subjects sign symptom history brain metastasis must CT MRI scan brain within 1 month prior start protocol therapy . Subjects spinal cord nerve root compression complete treatment least 4 week start protocol therapy stable without steroid treatment least one week start protocol therapy allow . Subjects leptomeningeal metastasis allow . 4 . Any following hematologic abnormality : Hemoglobin &lt; 9.0 g/dL ANC &lt; 1500 per mm3 Platelet count &lt; 100,000 per mm3 5 . Any following serum chemistry abnormality : Total bilirubin &gt; 1.5 × ULN ( &gt; 2.5 mg/dL patient Gilbert 's syndrome ) AST ALT &gt; 2.5 × ULN ( &gt; 5 × ULN subject liver metastasis ) GGT &gt; 2.5 x ULN ( &gt; 5 × ULN subject liver metastasis ) Alkaline phosphatase &gt; 2.5 × ULN ( &gt; 5 × ULN subject liver bone metastasis ) Serum albumin &lt; 3.0 g/dL Serum creatinine &gt; 1.5 × ULN Proteinuria &gt; 2.5 g/24 hour 3+ urine dipstick Any ≥ Grade 3 laboratory abnormality baseline ( list ) 6 . Significant cardiovascular disease , include : Clinically symptomatic heart failure . Subjects history heart failure must ECHO MUGA scan document leave ventricular ejection fraction ( LVEF ) &gt; 45 % prior start protocol therapy Uncontrolled hypertension : Blood pressure &gt; 140/90 mm Hg 2 antihypertensive medication , two consecutive measurement obtain least 24 hour apart . Subjects history hypertension must stable dos antihypertensive drug ≥ 2 week prior start protocol therapy . Myocardial infarction within 3 month prior start protocol therapy 7 . Baseline neuropathy &gt; Grade 1 8 . Subjects delay heal wound , ulcer , and/or bone fracture 9 . Serious/active infection infection require parenteral antibiotic 10 . Inadequate recovery prior surgical procedure ; major surgical procedure within 6 week prior start protocol therapy . 11 . Inability comply protocol requirement 12 . Ongoing hemoptysis history clinically significant bleeding within 6 month prior start protocol therapy 13 . Cerebrovascular accident within 12 month start protocol therapy , peripheral vascular disease claudication walk less 1 block . 14 . Deep venous thrombosis pulmonary embolus within 6 month prior start protocol therapy 15 . Subjects `` currently active '' second primary malignancy nonmelanoma skin cancer . Subjects consider `` currently active '' malignancy complete anticancer therapy disease free &gt; 2 year . 16 . Known concomitant genetic acquire immune suppression disease HIV 17 . Treatment systemic hormonal therapy within 3 week prior start protocol therapy , exception : Hormonal therapy appetite stimulation contraception Nasal , ophthalmic , inhaled topical steroid preparation Oral replacement therapy adrenal insufficiency Lowdose maintenance steroid therapy ( equivalent prednisone 10mg/day ) condition Hormone replacement therapy 18 . Herbal preparations/supplements ( except daily multivitamin/mineral supplement contain herbal component ) CYP3A4 inhibitor within 2 week prior start protocol therapy . 19 . Full dose oral anticoagulation warfarin , acenocoumarol , fenprocoumon , similar agent . If previously receive type agent , minimum washout 1 week document INR &lt; 1.5 x ULN require prior start protocol therapy . Full dose anticoagulation low molecular weight heparin unfractionated heparin administer subcutaneously allow .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>tivozanib</keyword>
	<keyword>AV-951</keyword>
</DOC>